Trades on 2 secondary markets

Scribe Therapeutics

Scribe Therapeutics is a clinical-stage biotechnology company founded in 2018 and headquartered in Alameda, California, engineering CRISPR-based genetic medicines through its proprietary "CRISPR by Design" platform. Co-founded by molecular engineers Benjamin Oakes, Brett Staahl, and David Savage alo

minimal 11.9 / 100 0 APIs View provider profile →

Company Biotechnology CRISPR Gene Editing Genetic Medicine Therapeutics

Scribe Therapeutics is an API provider whose private shares are listed on 2 secondary markets: Forge Global, Nasdaq Private Market.

Where It Trades

F Forge Global View listing → N Nasdaq Private Market View listing →

Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.